Eli Lilly and Co has signed a collaboration agreement with Verve Therapeutics Inc, a clinical stage US genetic medicines company, to develop a product that can treat atherosclerotic cardiovascular disease. This is a disorder arising from a thickening of the arteries, restricting the flow of blood to organs and tissues. An increase in a specific type of lipoprotein can cause the disease. The amount of this protein in individuals is congenital.
